Interleukin-27 receptor limits atherosclerosis in Ldlr-/- mice

Circulation Research

Volumn 111, Issue 10, 2012, Pages 1274-1285

  Koltsova, Ekaterina K ^a   Kim, Gisen ^a   Lloyd, Kathleen M ^a   Saris, Christiaan J M ^b   Von Vietinghoff, Sibylle ^a,c   Kronenberg, Mitchell ^a   Ley, Klaus ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b AMGEN INC   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

atherosclerosis; chemokines; cytokines; inflammation; leukocyte recruitment; vascular inflammation

Indexed keywords

CD11B ANTIGEN; CD45 ANTIGEN; GLYCOPROTEIN P 15095; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIGENS, CD11B; ANTIGENS, CD11C; AORTA; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL2; FEMALE; INTERLEUKIN-17; INTERLEUKINS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYELOID CELLS; RECEPTORS, CYTOKINE; RECEPTORS, LDL; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84868686357     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.277525     Document Type: Article

References (58)

1. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:969-979.
2. Zernecke A, Weber C. Chemokines in the vascular infammatory response of atherosclerosis. Cardiovasc Res. 2010;86:192-201.
3. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506-1516.
4. Galkina E, Ley K. Immune and infammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197.
5. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Infuence of interferon-gamma on the extent and phe-notype of diet-induced atherosclerosis in the LDLR-defcient mouse. Arterioscler Thromb Vasc Biol. 2003;23:454-460. (Pubitemid 36337222)
6. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752-2761. (Pubitemid 27259823)
7. Brånén L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004;24:2137-2142. (Pubitemid 39482442)
8. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-defcient mice. Am J Pathol. 2003;163:1117-1125. (Pubitemid 37040147)
9. Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-defcient mice. Arterioscler Thromb Vasc Biol. 1999;19:734-742.
10. Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ, van Snick J, Kuiper J. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112:1054-1062. (Pubitemid 41174584)
11. Zhang X, Niessner A, Nakajima T, Ma-Krupa W, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res. 2006;98:524-531.
12. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K, Galkina E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-defcient mice. Circulation. 2010;121: 1746-1755.
13. von Vietinghoff S, Koltsova EK, Mestas J, Diehl CJ, Witztum JL, Ley K. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated mac-rophage accumulation. J Am Coll Cardiol. 2011;57:2194-2204.
14. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-defcient Mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064-1071. (Pubitemid 34627904)
15. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:e17-e24.
16. Lutgens E, Daemen MJ. Transforming growth factor-beta: a local or systemic mediator of plaque stability? Circ Res. 2001;89:853-855. (Pubitemid 34627888)
17. Grainger DJ, Mosedale DE, Metcalfe JC, Böttinger EP. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci. 2000;113 (Pt 13):2355-2361. (Pubitemid 30599340)
18. Yoshida H, Miyazaki Y, Yoshiyuki M. Regulation of immune responses by interleukin-27. Immunol Rev. 2008;226:234-247.
19. Pfanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, Phillips JH, McClanahan TK, de Waal Malefyt R, Kastelein RA. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172:2225-2231. (Pubitemid 38182370)
20. Stumhofer JS, Hunter CA. Advances in understanding the anti-in-fammatory properties of IL-27. Immunol Lett. 2008;117:123-130.
21. Artis D, Villarino A, Silverman M, et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol. 2004;173:5626-5634. (Pubitemid 39392150)
22. Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, Yoshimura A, Yoshida H. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of pro-infammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol. 2006;177:5377-5385. (Pubitemid 44527610)
23. Kimura A, Naka T, Kishimoto T. IL-6-dependent and-independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA. 2007;104:12099-12104. (Pubitemid 47185636)
24. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N. Interleukin 27 limits autoimmune encephalo-myelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7:929-936. (Pubitemid 44263906)
25. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454-465. (Pubitemid 46834848)
26. Niedbala W, Cai B, Wei X, Patakas A, Leung BP, McInnes IB, Liew FY. Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis. 2008;67:1474-1479.
27. Shimizu S, Sugiyama N, Masutani K, Sadanaga A, Miyazaki Y, Inoue Y, Akahoshi M, Katafuchi R, Hirakata H, Harada M, Hamano S, Nakashima H, Yoshida H. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice defcient for IL-27 receptor (WSX-1). J Immunol. 2005;175:7185-7192. (Pubitemid 41713412)
28. Kempe S, Heinz P, Kokai E, Devergne O, Marx N, Wirth T. Epstein-barr virus-induced gene-3 is expressed in human atheroma plaques. Am J Pathol. 2009;175:440-447.
29. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, von Vietinghoff S, Galkina E, Miller YI, Acton ST, Ley K. Dynamic T cell-APC interactions sustain chronic infammation in atherosclerosis. J Clin Invest. 2012;122:3114-3126.
30. Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43:402-407.
31. Shahrara S, Pickens SR, Mandelin AM 2nd, Karpus WJ, Huang Q, Kolls JK, Pope RM. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol. 2010;184:4479-4487.
32. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129:311-321.
33. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Natoli E, Rollins BJ, Milos PM. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-defcient mice. Arterioscler Thromb Vasc Biol. 1999;19:1518-1525. (Pubitemid 29263023)
34. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-974. (Pubitemid 47300011)
35. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364-2367. (Pubitemid 29477837)
36. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apo-lipoprotein E-defcient mice. Atherosclerosis. 2001;156:315-320. (Pubitemid 32522911)
37. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, Guo C, Wang Q, Wang X, Ma C, Zhang Y, Chen W, Zhang L. A critical function of Th17 proinfammatory cells in the development of atherosclerotic plaque in mice. J Immunol. 2010;185:5820-5827.
38. van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr defcient mice. Biochem Biophys Res Commun. 2009;388:261-265.
39. Erbel C, Chen L, Bea F, Wangler S, Celik S, Lasitschka F, Wang Y, Böckler D, Katus HA, Dengler TJ. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-defcient mice. J Immunol. 2009;183:8167-8175.
40. Chen S, Shimada K, Zhang W, Huang G, Crother TR, Arditi M. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneu-moniae infection-accelerated atherosclerosis in mice. J Immunol. 2010;185:5619-5627.
41. Madhur MS, Funt SA, Li L, Vinh A, Chen W, Lob HE, Iwakura Y, Blinder Y, Rahman A, Quyyumi AA, Harrison DG. Role of interleukin 17 in infammation, atherosclerosis, and vascular function in apolipoprotein e-defcient mice. Arterioscler Thromb Vasc Biol. 2011;31:1565-1572.
42. Usui F, Kimura H, Ohshiro T, Tatsumi K, Kawashima A, Nishiyama A, Iwakura YI, Ishibashi S, Takahashi M. Interleukin-17 defciency reduced vascular infammation and development of atherosclerosis in western diet-induced apoe-defcient mice. BBRC. 2012;420:72-77.
43. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, Villarino AV, Huang Q, Yoshimura A, Sehy D, Saris CJ, O'Shea JJ, Hennighausen L, Ernst M, Hunter CA. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic infammation of the central nervous system. Nat Immunol. 2006;7:937-945. (Pubitemid 44263907)
44. Takeda A, Hamano S, Yamanaka A, Hanada T, Ishibashi T, Mak TW, Yoshimura A, Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol. 2003;170:4886-4890. (Pubitemid 36554716)
45. Rosas LE, Satoskar AA, Roth KM, Keiser TL, Barbi J, Hunter C, de Sauvage FJ, Satoskar AR. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-defcient mice display enhanced resistance to leish-mania donovani infection but develop severe liver immunopathology. Am J Pathol. 2006;168:158-169. (Pubitemid 43062569)
46. Villarino A, Hibbert L, Lieberman L, Wilson E, Mak T, Yoshida H, Kastelein RA, Saris C, Hunter CA. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity. 2003;19:645-655. (Pubitemid 37490790)
47. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, Gaffen SL. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem. 2004;279:2559-2567. (Pubitemid 38114241)
48. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol. 2007;179:4135-4141.
49. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol. 2006;7:311-317.
50. Charo IF, Ransohoff RM. The many roles of chemokines and chemo-kine receptors in infammation. N Engl J Med. 2006;354:610-621. (Pubitemid 43209108)
51. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-defcient mice. Mol Cell. 1998;2:275-281. (Pubitemid 128373654)
52. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-964. (Pubitemid 41746764)
53. Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on infamed en-dothelium. Blood. 2003;102:1985-1988. (Pubitemid 37122370)
54. Soehnlein O, Weber C. Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol. 2009;31:35-47.
55. Weber C, Meiler S, Döring Y, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest. 2011;121:2898-2910.
56. Zrioual S, Toh ML, Tournadre A, Zhou Y, Cazalis MA, Pachot A, Miossec V, Miossec P. IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in syn-oviocytes and are overexpressed in rheumatoid blood. J Immunol. 2008;180:655-663.
57. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. Preferential recruitment of CCR6-expressing Th17 cells to infamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803-2812. (Pubitemid 350179551)
58. Surmi BK, Hasty AH. The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul Pharmacol. 2010;52:27-36.